Evolent Health (EVH) Cash from Financing Activities (2015 - 2026)

Evolent Health has reported Cash from Financing Activities for 12 years, with the latest figure at -$11.0 million in Q2 2026.

• On a quarterly basis, Cash from Financing Activities fell 23.14% year-over-year to -$11.0 million in Q2 2026; TTM through Jun 2026 was -$149.8 million, a 180.18% decrease from a year earlier, with the FY2025 full-year figure at -$35.9 million, down 6258.23% from the prior year.
• Cash from Financing Activities was -$11.0 million for Q2 2026 at Evolent Health, down from -$4.0 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $379.7 million in Q1 2023, with the low at -$103.4 million in Q2 2024.
• Average Cash from Financing Activities over 5 years is $20.1 million, with a median of -$9.0 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities jumped 26901.72% in 2022, then slumped 677.15% in 2023.
• Over 5 years, Cash from Financing Activities stood at -$10.9 million in 2022, then plunged by 677.15% to -$84.4 million in 2023, then surged by 214.93% to $96.9 million in 2024, then tumbled by 195.97% to -$93.0 million in 2025, then jumped by 88.18% to -$11.0 million in 2026.
• The last three Cash from Financing Activities figures came in at -$11.0 million (Q2 2026), -$4.0 million (Q1 2026), and -$93.0 million (Q4 2025), per Business Quant data.